— Manufacturer setting a price for oveporexton to align with value would help promote broad patient access —

BOSTON, June 8, 2026 – The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of oveporexton (Takeda Pharmaceutical Co., Ltd.) for narcolepsy type 1.

ICER’s report on this therapy was the subject of the May 2026 public meeting of the Midwest CEPAC, one of ICER’s three independent evidence appraisal committees. 

Downloads: Final Evidence Report | Report-at-a-Glance | Policy Recommendations 

“The narcolepsy treatment landscape includes several pricey medications that do not provide complete relief for patients,” said ICER’s Senior Vice President of Research, Foluso Agboola, MBBS, MPH.  “ICER’s analyses found that oveporexton, the first medication for narcolepsy type 1 that directly addresses the underlying cause of the condition, is effective in promoting wakefulness, improving quality of life, and appears to offer better health benefits than current options. The manufacturer choosing a value-based price for oveporexton would help de-escalate the cycle of high prices being met with onerous access challenges. Our independent analysis can offer a roadmap for improving affordability and access for patients and the health system.”

ICER’s Public Meeting: Voting Results on Clinical Effectiveness and Benefits Beyond Health 

ICER assessed, and the independent appraisal committee voted on the evidence for the net health benefit of oveporexton:

  • The panelists unanimously found (13-0) that current evidence is adequate to demonstrate a net health benefit for oveporexton when compared to no pharmacological treatment.
  • A majority of panelists (8-5) found that current evidence is adequate to demonstrate a net health benefit for oveporexton when compared to modafinil with venlafaxine.
  • A majority of panelists (10-3) found that current evidence is adequate to demonstrate a net health benefit for oveporexton when compared to sodium oxybate.
  •  A majority of panelists (11-2) found that current evidence is adequate to demonstrate a net health benefit for oveporexton when compared to pitolisant.

Panel members also weighed potential benefits and disadvantages beyond the direct health effects and weighed special ethical obligations. Voting highlighted the following as particularly important for payers and other policymakers to note: 

  • Oveporexton is likely to substantially improve caregivers’ quality of life and/or ability to pursue their own education, work, and family life.

ICER’s Public Meeting: Voting Results on Long-Term Value for Money 

Consistent with ICER’s process, because there is no firm estimate yet of a potential launch price for the treatment, the panel did not take a vote on oveporexton’s long-term value for money. 

Oveporexton has not yet been approved by the FDA for narcolepsy type 1. The manufacturer has not yet announced a US price for the therapy, if approved. ICER calculated a health benefit price benchmark (HBPB) between $50,400 and $59,400 per year.

Key Policy Recommendations 

ICER’s independent assessment of value informs the critical decisions that stakeholders across the US health system need to make around pricing and coverage. Following the voting session, a policy roundtable of experts — including clinical experts, patients and patient advocates, the manufacturer, and representatives of US payers — convened to discuss the pricing implications and recommendations to ensure fair access. Key recommendations stemming from the roundtable discussion include: 

  • Manufacturers have a responsibility to set prices at levels that will foster affordability and good access for all patients by aligning prices with the patient-centered therapeutic value of their treatments.
  • If oveporexton is priced in line with its value, because it has a novel mechanism of action that directly addresses the underlying cause of NT1, it would not be appropriate for payers to restrict access to oveporexton using step therapy.
  • Patient organizations have a powerful voice to create significant pressure for fair pricing and appropriate insurance coverage across all sectors of the health system. 

ICER’s detailed set of policy recommendations is available in the Final Evidence Report and in the standalone Policy Recommendations document. 

About ICER 

The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit www.icer.org.